Characteristic | Complete psoriatic arthritis cohort (n = 566) | Etanercept (n = 316) | Infliximab (n = 162) | Adalimumab (n = 88) | P value |
---|---|---|---|---|---|
Demographic | |||||
Age (years) | 45.7 ± 11.1 | 45.8 ± 11.1 | 44.8 ± 11.0 | 47.0 ± 11.6 | 0.325 |
Female | 300 (53.0) | 162 (51.3) | 89 (54.9) | 47 (53.4) | 0.581 |
Disease duration (years) | 12.4 ± 8.7 | 12.8 ± 9.0 | 12.2 ± 8.0 | 11.4 ± 8.4 | 0.384 |
Patients with other baseline co-morbidities | 375 (62.9) | 191 (57.4%) | 117 (68.4%) | 67 (72.8%) | 0.111 |
Disease | |||||
28-Tender joint count | 13.4 ± 7.7 | 13.5 ± 7.6 | 14.1 ± 8.1 | 12.1 ± 7.1 | 0.346 |
28-Swollen joint count | 8.9 ± 6.1 | 8.8 ± 6.1 | 8.8 ± 6.4 | 9.7 ± 5.7 | 0.293 |
Erythrocyte sedimentation rate (mm) | 40.5 ± 29.0 | 39.4 ± 28.1 | 44.2 ± 31.4 | 37.7 ± 27.4 | 0.459 |
C-reactive protein level (mg/dl) | 39.3 ± 47.1 | 35.4 ± 41.8 | 47.8 ± 50.0 | 35.0 ± 56.6 | 0.787 |
28-joint Disease Activity Score | 6.4 ± 5.6 | 6.1 ± 1.2 | 7.3 ± 10.1 | 6.0 ± 1.0 | 0.464 |
Health Assessment Questionnaire | 1.9 (1.4 to 2.3) | 1.8 (1.4 to 2.3) | 2.0 (1.4 to 2.4) | 1.8 (1.1 to 2.3) | 0.581 |